The recent dramatic rise in methamphetamine (METH)-related trafficking, emergency room visits, and deaths has been declared a severe national crisis by the U.S. Department of justice. Because of these disturbing trends in heavy METH abuse, it is important to elucidate the causes of METH-induced long-term deficits to striatal monoaminergic systems. It has been demonstrated that METH dramatically increases extracellular dopamine (DA) and the large quantities of the released DA in the presence of O2 and reactive iron, may oxidize to form cytotoxic free radicals. Because of the reactive nature of DA, and the finding of this and other laboratories that the formation of reactive oxygen species (ROS) correlates with METH- induced monoaminergic changes, we hypothesize that: Generation of DA- related ROS is a major contributor to the neurochemical deficits occurring in striatal monoaminergic systems after high doses of METH. This hypothesis will be tested by monitoring drug-induced changes in monoamine neurochemical parameters and oxidation products of salicylate in order to achieve the following Specific Aims:
Specific Aim A. Establish the optimal conditions to assess ROS generation after METH administration to (a) confirm that high doses of METH increase ROS formation, (b) correlate ROS formation with METH-induced monoamine deficits and (c) identify experimental conditions for the remainder of the studies.
Specific Aims B and C. Determine if factors that alter METH-induced monoamine deficits influence its ability to produce ROS (Specific Aim B) and determine if factors that are associated with ROS production from DA influence METH-induced monoamine deficits (Specific Aim C). These studies will help link METH-induced ROS formation and monoamine deficits as well as elucidate related mechanisms.
Specific Aim D. Demonstrate that besides the well-established long-term monoamine deficits, increased ROS caused by high doses of METH also effect dramatic, rapid, but reversible, reductions in DA transporter activity. This exciting new finding will be characterized and the role of ROS in this effect examined. These studies will elucidate the role of DA-related ROS in monoamine responses to the abuse of high doses of METH and provide insight into the mechanisms associated with DA-linked neurological diseases, such as Parkinson's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA000869-23
Application #
2713051
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Lin, Geraline
Project Start
1973-11-01
Project End
2000-05-31
Budget Start
1998-06-20
Budget End
1999-05-31
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Fricks-Gleason, Ashley N; German, Christopher L; Hoonakker, Amanda J et al. (2016) An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity. Synapse 70:139-46
McFadden, Lisa M; Vieira-Brock, Paula L; Hanson, Glen R et al. (2015) Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure. Neuropharmacology 93:146-54
Baladi, Michelle G; Newman, Amy H; Nielsen, Shannon M et al. (2014) Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia. Eur J Pharmacol 732:105-10
German, Christopher L; Fleckenstein, Annette E; Hanson, Glen R (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97:2-8
Baladi, Michelle G; Nielsen, Shannon M; Umpierre, Anthony et al. (2014) Prior methylphenidate self-administration alters the subsequent reinforcing effects of methamphetamine in rats. Behav Pharmacol 25:758-65
McFadden, Lisa M; Stout, Kristen A; Vieira-Brock, Paula L et al. (2012) Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse 66:240-5
McFadden, Lisa M; Hunt, Madison M; Vieira-Brock, Paula L et al. (2012) Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations. Drug Alcohol Depend 126:87-94
McFadden, Lisa M; Hadlock, Greg C; Allen, Scott C et al. (2012) Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther 340:295-303
German, Christopher L; Hanson, Glen R; Fleckenstein, Annette E (2012) Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem 123:288-97
Hadlock, Gregory C; Nelson, Chad C; Baucum 2nd, Anthony J et al. (2011) Ex vivo identification of protein-protein interactions involving the dopamine transporter. J Neurosci Methods 196:303-7

Showing the most recent 10 out of 162 publications